Understanding tumor genomic heterogeneity may offer vital information in an age of targeted therapy for renal cell carcinoma. We sought to investigate hallmark truncal chromosomal alterations between conventional, sarcomatoid, and matched metastatic tumor foci in clear cell and papillary renal cell carcinomas. A retrospective review identified 58 cases including clear cell (CCRCC) and papillary renal cell carcinomas (PRCC). All cases contained sarcomatoid transformation. Additionally, 10 of 58 patients had matched metastatic disease available for analysis. Three separate foci of conventional and sarcomatoid morphologies were analyzed in each tumor using dual color interphase fluorescence in situ hybridization. In the CCRCC cohort, hallmark chromosome 3p deletion was identified in 71% of cases (37/52). Complete concordance of chromosomal status between intratumoral foci in sarcomatoid and conventional foci was 89% and 86%, respectively. Overall chromosome 3p status between matched conventional and sarcomatoid morphologies was identified in 98% of cases (51/52). Hallmark 3p deletion was present in 91% of CCRCC metastatic samples (10/11) and was concordant with the matched primary CCRCC tumor in 91% (10/11). In the PRCC cohort, trisomy 7 and 17 was identified in all six cases (6/6). Complete concordance between intratumoral foci of trisomy 7 and 17 was 83% (5/6). Trisomy 7 and 17 were identified in all metastatic PRCC samples with 100% concordance with the matched primary tumor. These data show the relative preservation of truncal chromosomal abnormalities between conventional and sarcomatoid morphologic as well as matched metastatic settings.
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| INTRODUCTION
The morphological and genetic complexities of renal cell carcinoma (RCC) have been extensively studied. Additionally, several recent studies have used genomic sequencing to highlight intratumoral genetic heterogeneity. [1] [2] [3] [4] [5] [6] Such complexities are compounded by the predisposition of a subset of RCC to undergo sarcomatoid differentiation. RCC with sarcomatoid features, regardless of the conventional morphologic subtype, has been shown to be associated with an overall worse prognosis. 7 Accordingly, studies have attempted to characterize the extent of intratumoral heterogeneity within sarcomatous tumor components and compare the differences between conventional (eg, epithelial) and sarcomatous elements. 8, 9 Intratumoral genetic heterogeneity, particularly in the setting of divergent morphologic features and/or high clinical stage, may have significant impact on treatment options for patients, especially those with metastatic disease. 10 Hallmark chromosomal gains and losses in primary RCC have been characterized, most notably the presence of chromosome 3p deletion in clear cell RCC (CCRCC) and trisomy 7
and 17 in papillary RCC (PRCC). [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Prior studies have attempted to compare intratumoral concordance of hallmark chromosomal gains and losses and subsequent concordance with matched metastases. [21] [22] [23] We herein investigate the preservation of hallmark chromosomal abnormalities along with intratumoral concordance in the setting of matched sarcomatous transformation and matched metastatic disease in CCRCC and PRCC.
| MATERIALS AND METHODS
Fifty-eight patients diagnosed with either CCRCC (52 patients) or PRCC (6 patients) with sarcomatoid transformation between 1995 and 2016 were retrieved from our institution's surgical pathology files.
Histopathologic features of each case were evaluated by a single senior genitourinary pathologist (LC) and confirmed using diagnostic criteria set forth in the World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs. 24 Appropriate sections containing both conventional and sarcomatoid tumor foci were selected for subsequent analysis. Specimens of biopsy/resection-proven metastatic tumors of the patients were also identified and lesions were matched with primary lesions for analysis. This study was approved by the Institutional Review Board.
Formalin-fixed, paraffin-embedded tissue blocks of each tumor were obtained based on correlation with the reviewed hematoxylin and eosin-stained glass slides demonstrating conventional (epithelial) and sarcomatoid morphologies. Three separate foci of conventional and sarcomatoid morphologies were analyzed in each primary tumor.
When available, three foci of metastatic RCC were marked, analyzed, and compared to their primary RCC ( Figure 1 ). Fluorescence in situ hybridization (FISH) analysis was performed on each of these selected foci to identify the presence of hallmark chromosomal abnormalities associated with CCRCC and PRCC including deletion of 3p and trisomy 7 and 17, respectively, as described previously. 25, 26 Selected slides were deparaffinized with two washes of xylene, 15 min each; washed twice with absolute ethanol, 10 min each; and airdried in a fume hood. Subsequently, the slides were treated with 0.1 mM citric acid (pH 6.0) at 95°for 10 min, rinsed in distilled water for 3 min, and followed by a wash of standard saline citrate (2 × SSC) for Chromosome 3p deletion was considered to be characteristic of CCRCC and trisomy of chromosomes 7 and/or 17 was considered characteristic of PRCC.
| RESULTS
We identified 58 patients with CCRCC (n = 52) or PRCC (n = 6) tumors with sarcomatoid features, additionally 13 samples (CCRCC n = 11; PRCC n = 2) of metastatic disease from 10 different patients 
| Clear cell renal cell carcinoma
The study cohort of CCRCC with sarcomatoid features included 52
patients with a male-to-female ratio of 1. 
| DISCUSSION
In this study, we evaluated the presence and maintenance of truncal chromosomal aberrations of multiple tumor foci in matched | 2531
Approximately 5-10% of RCC have some component of sarcomatoid morphology. 7 The underlying mechanisms of transition to sarcomatoid differentiation have been extensively hypothesized; however, regardless of such purported mechanisms causing this divergence, limited prior study shows chromosomal aberrations of the conventional components appear to be maintained. 30 Prior landmark genomic studies in RCC subtypes typically excluded cases with divergent morphology, which explains the paucity of data evaluating preservation of these recurrent chromosomal aberrations in the setting of sarcomatoid differentiation. 9 Cancer evolution remains an extensively studied concept and encompasses a complicated series of molecular events. While hypotheses and opinions differ, it appears that RCCs arise from a single clonal event which subsequently branch (or "braid") into subclonal events. A key point of contention is how these subclones interact, if at all, as the tumor evolves. 17, 20, 31 Herein lays the debate between linear versus braided evolution from a truncal event in tumorigenesis. 32 Furthermore, the "braided" model hypothesizes that spatially heterogenous mutations may happen at different points in time but the overall genomic profile inevitably becomes similar. FISH is determined by probe size and labeling methods. 16 By using plasmid or oligo probes, detection could increase resolution to 2-3 KB level. These types of probes are especially useful for the detection of micro-deletions but with reduced sensitivity. It is still unclear how these small genetic lesions interact with clinical tumor progression or contribute to possible resistance to treatment. 21 Regardless, many of these subclones, while being genetically distinct, do share identical driver mutations. 29, 34, 35 Regardless of the role of subclones in tumor evolution, chromosome 3p abnormalities in CCRCC and trisomy 7/17 in PRCC remain significant in tumorigenesis and targeted treatment. 8, 25 In CCRCC, these abnormalities directly relate to the VHL gene, which is located at 3p25. Variations in VHL expression have direct consequences to three key pathways including the hypoxia-inducible factor (HIF), mammalian target of rapamycin (MTOR), and overexpression of vascular endothelial growth factor/platelet-derived growth factor (VEGF). 14,17,22,32 VHL is a ligase responsible for degrading HIF1/2A. Given the vascular nature of CCRCC, the angiogenesis seen in these lesions is likely a direct result of this uninhibited activation. 36 The importance of chromosome 3p deletion and VHL genetic alterations stems from their function as truncal drivers in the development of CCRCC. 4, 16, 17, 19 Mutations in PBRM1, SETD2, and BAP1 have been identified in CCRCC and are notably located on the short arm of chromosome 3p (all within a 50-Mb region), highlighting further importance in assessing 3p mutations/ deletions. 14, 37 Similar to the hallmark chromosome 3p deletion in CCRCC, the study by Kovac et al describes similar evolution of PRCC from a truncal chromosomal alteration, such as trisomy chromosome 7 and/or 17, followed by subsequent subclonal mutations. 40 Some evidence has been shown to suggest chemotherapeutic agents used to treat CCRCC, including sunitinib, sorafenib, and mTOR inhibitors such as everolimus and temsirolimus, also show efficacy in other RCC subtypes including PRCC and chromophobe renal cell carcinoma. 41 Interestingly, foretinib appears to benefit patients with germline MET mutations compared to all PRCC patients. 40 In current models of RCC evolution and of cancer progression, prior data suggest that conventional and sarcomatoid tumor components likely arise from a common progenitor cell with subsequent subclonal populations arising as the tumor progresses. 8, 9 It has been reported that areas of sarcomatoid differentiation in RCC have increased mutations and greater loss of heterozygosity. 42 identified in a single case within our current study. 5 Ito et al have Other histologic types of RCC, such as chromophobe RCC, have been shown to contain similar preservation of genetic abnormalities between primary and matched metastatic lesions. [46] [47] [48] Several studies have argued that metastatic lesions are less heterogeneous, but also completely different genetically, from their primary lesion. 5 Our study highlighted complete chromosomal concordance between all tumor foci within each metastatic lesion in both CCRCC and PRCC.
Overall, the 5-year survival for RCC ranges from 61 to 72%. 49, 50 Regardless of the histologic subtype, high-stage RCC disease has a 5-year survival rate of 53% and only 8% with metastatic disease. As previously stated, studies have postulated that intratumoral heterogeneity contributes to therapeutic resistance likely secondary to intratumoral genetic heterogeneity by a combination of genomic instability and Darwinian cancer evolution. 2, 10, 29 Furthermore, these studies maintain that genomic/genetic reprofiling of metastatic lesions could be a novel approach to identify causes of resistance to anti-VEGF inhibitors. 23 Genetic overlap between CCRCC and PRCC, upwards of 100 genes, has been described. 63 Our current study has corroborated many prior molecular findings in CCRCC and PRCC, such as hallmark abnormalities and relative preservation of chromosomal status by multifocal analysis. Unfortunately, this has not elucidated why efficacy of chemotherapeutic agents is so poor. Given that mutations/alterations in CCRCC, including lesser known mutations such as BAP1 and SETD2, typically occur on the short arm of 3p, current regiments targeting these regions have done little to improve overall survival and disease-free survival.
14 While we may have been able to prove that CCRCC and PRCC tumors retain similar chromosomal status regardless of tumor divergence or metastasis, this unfortunately also highlights that tumor progression likely goes beyond the pathways described above.
One potential limitation identified in this study is the ability to identify all possible chromosome 3p genetic alterations in clear cell renal cell carcinoma by FISH studies. [16] [17] [18] [19] In the current study, the BAC clone probe used was 169 K in size. According to other metaphase and molecular studies, the majority of the 3p deletions in CCRCC were in the pattern of 3p13-ptar or 3p25-pter deletion, and microdeletions
were not typically reported in CCRCC. 4, 13, 14, 66, 67 Since the previously reported deletions were far greater in size than that of the probe (169KB), we felt a vast majority would be detectable by the probe. The While a majority of allelic loss occurs by simple deletion, a subset of tumors have been shown to incur loss of chromosome region by uniparental disomy (UPD) or copy-neutral loss of heterozygosity (LOH). 68 Traditionally UPD, which occurs when a person inherits two chromosomal copies from the same parent and none from the other, had been associated with inherited-type diseases. 18 
